Scientists have identified 16 genes that breast cancer cells use to survive in the bloodstream after they've escaped the low-oxygen regions of a tumor. Each is a potential therapeutic target to stop ...

GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...

Robert F. Kennedy Jr is known as a persistent critic of vaccine safety and is a longtime antagonist of the Food and Drug ...

The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Mr. Shah Coherent Market Insights Pvt. Ltd. +1 206-701-6702 email us here Visit us on social media: Facebook X LinkedIn ...

Onyema Ogbuagu, an expert in infectious diseases and a Nigerian-born doctor, was central in Pfizer’s development of a ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

The media giant would separate from the Paris-based conglomerate and is expected to float in London on 16 December, according ...

The global glucosamine supplement market is projected to grow from USD 583.6 million in 2023 to USD 932.7 million by 2033, expanding at a CAGR of 4.8%, according to Future Market Insights. The rising ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

GSK stock plunged Wednesday after sales of its RSV vaccine, Arexvy, skidded and widely missed Wall Street's expectations.